Medable Secures $91 Million Funding to Accelerate Industry Shift to Digital and Decentralized Clinical Trials

Nov 19, 2020•over 4 years ago

Amount Raised

$91 Million

Palo Alto

Description

Medable Inc. today announced $91 million in new funding to accelerate the life sciences industry’s shift to digital and decentralized clinical trials. The Series C funding round was led by Sapphire Ventures, with follow-on investment from existing investors GSR Ventures, PPD, Inc. (Nasdaq:PPD) and Streamlined Ventures

Company Information

Company

Sapphire Ventures

Location

Palo Alto, California, United States

About

Sapphire Ventures is a venture capital firm focused on helping innovative technology companies become global category leaders. Leveraging nearly two decades of experience and an extensive global executive network, Sapphire invests capital, resources and expertise to enable its portfolio companies to scale rapidly through a powerful business development, marketing and talent platform. With more than $4 billion in assets under management across its Sapphire Ventures, Sapphire Partners and Sapphire Sport investment platforms, Sapphire is positioned to elevate companies across technology sectors to the global stage. To learn more about Sapphire Ventures, please see: https://sapphireventures.com/.

FundzWatch™ Score

Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech